CD44 and cancer: MiR-204 inhibits CD44 (cancer stem cell marker) in HCC827/gef and H1975/AZD18 NSCLC cells (resistant cells to osimertinib by continuous exposure to this TKI), repressing the pluripotency of these cells by reducing spheroid formation and promoting osimertinib-induced apoptosis.